Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Transl Med
Auteurs principaux: Morello, Silvana, Capone, Mariaelena, Sorrentino, Claudia, Giannarelli, Diana, Madonna, Gabriele, Mallardo, Domenico, Grimaldi, Antonio M., Pinto, Aldo, Ascierto, Paolo Antonio
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716054/
https://ncbi.nlm.nih.gov/pubmed/29202855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-017-1348-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires